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The mechanistic basis for prostacyclin
action in pulmonary hypertension
dicted from vasodilator testing.3 This strongly suggests
additional benefits of PGI2, probably relating to anti-pro-
liferative, anti-thrombotic and anti-inflammatory proper-
ties of this agent in the pulmonary vasculature. It is assumed
this translates into a regression of the vascular remodelling
process,5 though evidence so far is lacking in IPAH patients.6
Indeed lesion formation was actually reported to be more
extensive in IPAH patients on combined prostacyclin and
bosantan (mixed endothelin antagonist) therapy.7
In this article, we will discuss the recent advances in our
understanding of the mechanistic basis for prostacyclin
therapy, highlighting differences in the pharmacological
action of prostacyclin agonists, the impact of PAH on
prostacyclin signalling through prostacyclin (IP) receptors
and peroxisome proliferator-activated receptors (PPARs),
and the complex effects of prostacyclin on vascular remod-
elling, which in the long term may cause these agents to fail. 
PROSTACYCLIN ANALOGUES 
Prostacyclin is clinically very hard to work with and has to
be refrigerated if not used immediately or in hotter climates,
the i.v. delivery system requires an ice pack. The half-life is
approximately 3 minutes when kept in buffer at a physio-
logical temperature, the vinyl-ether linkage making it sus-
ceptible to hydrolysis to 6-keto-PGF1α (Figure 1), a
chemically stable product but weak inhibitor of platelet
function and vascular tone.8 The metabolism is complex,
but 6-keto-PGF1α can be further metabolised in the kidney
to the 2,3-dinor derivative.8 Therefore, prostacyclin is typ-
ically monitored by measurement of 6-keto-PGF1α in plas-
ma or its derivative in urine, 2,3-dinor-6-keto-PGF1α. 
Given this inherent instability, chemists made modifica-
tions in the lower and upper side chains, giving rise to ana-
Pulmonary arterial hypertension (PAH) is a progressive disease
of the small pulmonary arteries in which patients suffer from
elevated pulmonary arterial pressure, right ventricular failure
and a reduction in gas exchange. Left untreated the median
survival from diagnosis is ~2.8 years, though outcome is
significantly worse if patients have underlying pulmonary
fibrosis or scleroderma. Injury to the endothelium probably
initiates the disease process, with increased production of
vasoconstrictors (endothelin and thromboxane) and growth
factors accompanying the loss of vasodilator and anti-platelet
agents, prostacyclin and nitric oxide, which results in vascular
remodelling. To date prostacyclin therapy still remains the most
efficacious treatment for PAH, although its short half-life and
cumbersome delivery (continuous infusion) meant analogues
with improved stability and alternative routes of delivery were
developed. Classically, prostacyclin agents are thought to
produce haemodynamic and anti-proliferative effects through
prostacyclin (IP) receptors coupled to cyclic AMP generation,
though other prostanoid receptors may contribute (EP2, EP4) or
counterbalance (EP1, EP3) these responses. Increasing evidence
suggests peroxisome proliferator-activated receptors (PPARs)
are also cellular targets for prostacyclin agonists, regulating
cell growth, inflammation and apoptosis through these
transcription factors. Activation involves ligand binding and/or
membrane receptors but probably not cyclic AMP. Here we
discuss recent advances in our understanding of PPARs and
how they may represent an important therapeutic target in PAH.  
Prostacyclin (PGI2) is a 20-carbon prostanoid deriva-tive formed within vascular endothelial and smoothmuscle cells by cyclooxygenase (mainly COX-2) medi-
ated oxidation of arachidonic acid.1 Back in 1976, Sir John
Vane and co-workers reported that arteries (but not
platelets) contained an enzyme (PGI2 synthase) which trans-
formed prostaglandin intermediates (endoperoxides) to an
unstable substance (PGI2) that inhibited platelet aggregation
(reviewed in Gryglewski1). This prostanoid was subse-
quently found to be a potent dilator of both the systemic and
pulmonary circulation and an inhibitor of smooth muscle
cell proliferation.1 In the early 1980s, Rubin and colleagues
were the first to give prostacyclin to adult patients with idio-
pathic pulmonary arterial hypertension (IPAH), showing it
could acutely reduce mean pulmonary arterial pressure and
pulmonary vascular resistance and increase cardiac output.2
Subsequently, a number of randomised controlled trials
of intravenous prostacyclin (epoprostenol) have described
improvements in pulmonary haemodynamics, exercise tol-
erance and clinical symptoms.3 Alongside epoprostenol,
other therapies have been developed, including endothelial
antagonists and phosphodiesterase (PDE) type five
inhibitors.4 These improve clinical symptoms in PAH,
though to date only prostacyclin has been shown to have a
significant impact on long-term survival.3,4 A key thing to
note is that <20% of PAH patients respond to vasodilator
therapy, and many have improvement exceeding that pre-
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Figure 1. Structures of
prostacyclin and its analogues.
Prostacyclin is a chemically
unstable prostaglandin which is
readily hydrolsed in a
physiological buffer to 6-keto-
PGF1α. It is also subject to
metabolism by 15 hydroxyl
prostaglandin dehydrogenase and
β-oxidation yielding the urinary
metabolite 2,3-dinor-6-keto-
PGF1α. To increase stability, a
series of modifications in the
structure of prostacyclin were
made, giving rise to chemically
stable analogues with longer
plasma half-lives (given as
terminal). Stability comes from a
hindered alcohol group at carbon
15 as well as an ether moiety
replacing the methyl group at
carbon 3 of the carboxylic acid
side chain.
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logues not readily hydrolysable in solution (Figure 1). For
example, the ability of treprostinil (formally UT-15) to
inhibit platelet aggregation is not compromised if incubat-
ed in human plasma for 4 hours at 37°C prior to transfer to
platelet-enriched plasma.8 Iloprost, which shares the same
pentanoic side chain to prostacyclin, will, however, very
slowly degrade at room temperature and is most suscepti-
ble to β-oxidation, making its terminal plasma half-life less
(20–30 minutes) than either beraprost (40–60 minutes) or
treprostinil (180–270 minutes).9–11 Several drug formula-
tions now exist for clinical use including intravenous (ilo-
prost, treprostinil), oral (beraprost, treprostinil), inhaled
(iloprost and treprostinil) and subcutaneous (treprostinil). 
CELLULAR TARGETS OF PROSTACYCLIN AND ANA-
LOGUES 
IP receptors versus PPARs
The classical way by which PGI2 (or its stable analogues) is
thought to exert its biological effects locally is through acti-
vation of plasma membrane prostacyclin (IP) receptors
coupled via Gs protein to adenylyl cyclase and cyclic AMP
(cAMP) production.12 Once elevated, cAMP is rapidly bro-
ken down by specific phosphodiesterases (PDE). In the lung
PDE 1, 3, 4 appear responsible for regulating basal levels
and analogue-induced elevation.13,14 However, PGI2 syn-
thase is also heavily expressed in the perinuclear regions of
cells, including in smooth muscle.15 Once formed, prosta-
cyclin can then directly interact with the ligand-binding
domain of a family of transcription factors called peroxi-
some proliferator-activated receptors (PPARs). Three main
isoforms exist, PPARα, PPARβ(δ) and PPARγ, regulating
diverse cellular processes including lipid and glucose
metabolism, insulin sensitivity, cell growth and inflamma-
tion.15–17 There is the potential for cross talk between IP
receptors and PPARs since cAMP-dependent protein
kinase A (PKA) is known to phosphorylate and activate
PPARs, although many other kinases can regulate activity
both in the absence and presence of ligands,17 suggesting
regulation by other receptor pathways. 
PGI2 signalling through PPARβ is thought to have impor-
tant roles in embryonic development, tumourigenesis,
apoptosis and endothelial cell survival.15,17 PGI2 is probably
an endogenous ligand for PPARα and PPARγ, though com-
plex regulation by other prostaglandin metabolites (e.g. 15-
Deoxy-Δ12,14-PGJ2) make its hard to assess the precise role
of these two isoforms.15,18 Nonetheless, PPARα is a very
important therapeutic target for the treatment of hyperlip-
idaemia (fibrates) and PPARγ for type 2 diabetes (glita-
zones), with increasing evidence suggesting they may also
be novel targets in inflammatory and remodelling lung dis-
eases.16,19,20
Some analogues, including beraprost and iloprost, but not
cicaprost, bind to and transcriptionally activate PPARs,15,21
though cicaprost is still capable of activating PPARγ in
HEK293 cells.22 The mechanism by which analogues acti-
vate PPARs has not been extensively investigated. However,
with respect to PPARγ, both IP receptor and IP receptor-
independent mechanisms have been reported, though this
does not appear to necessitate cAMP elevation but could
involve phosphorylation of the ligand-binding domain.22,23
Signalling through other prostanoid receptors
In trying to understand the cellular effects of prostacyclin,
one has to remember that it has poor selectivity for
prostanoid receptors, binding to and activating EP1, EP3 and
TP receptors, albeit at higher concentrations (15–45-fold
for EP1 and EP3 and <100-fold for TP) compared with the
corresponding natural ligand.24–26 Activation of these
receptors would tend to elevate Ca2+ and/or lower cAMP
through different G protein pathways,12,18 leading to vaso-
constriction, thrombosis and cell proliferation (Figure 2).
In human lung and platelets, EP3 and TP receptors are the
main prostanoid receptor to oppose signalling through IP
receptors, the exception being pulmonary veins where EP1
and TP receptors appear to counteract prostanoid-induced
relaxation.18,27 Thus prostacyclin has the potential for dele-
terious effects if IP receptor expression is compromised
and/or if TP/EP receptor signalling is enhanced. Indeed, in
mice genetically deficient in the IP receptor, vascular pro-
liferation and platelet activation are increased in response
to tissue injury, whereas the opposite occurs in TP receptor
knockout mice, suggesting the balance between these two
receptor pathways is crucial in maintaining vascular
homoeostasis.28 Moreover, thromboxane levels rise when
the IP receptor gene is deleted and the vasodilator response
to cicaprost is converted to vasoconstriction.28
As shown, all analogues bind potently to the IP receptor
with a similar affinity (Table 1). However, like prostacyclin,
iloprost has poor selectivity for prostanoid receptors, being
essentially equipotent at activating IP, EP1 and EP3 recep-
tors.12,29 Thus, it is not surprising that iloprost-induced
vasorelaxation can be enhanced by EP1 receptor blockade
in the isolated rabbit perfused lungs30 or in guinea pig
aorta.31 On the other hand, cicaprost responses in rat tail
artery are enhanced by blocking Gi/Go coupling, presumed
to relate to the EP3 receptor, which is negatively coupled to
adenylyl cyclase via Gi.32 In addition, cicaprost has signifi-
cant activity at the EP4 receptor, as does iloprost for the
human and rat but little for the mouse receptor (Table 1).
Despite the expression of EP4 receptors in the human lung,33
they do not appear to mediate prostanoid-induced relax-
ation of human pulmonary arteries; in veins they may,
though DP and IP receptors still assume the greater role.18,27
However, in situations where the IP receptor is downregu-
lated (in PAH or high cell passage number), EP4 receptors
may well generate sufficient cAMP for a functional response
on vascular tone or cell proliferation.33
Surprisingly little is known about the pharmacology of
treprostinil, though enhanced and more prolonged cAMP
generation compared to other analogues was reported in
Figure 2. Prostacyclin poorly
discriminates between prostanoid
receptors. Prostacyclin binds to
the IP receptor, which is coupled
via Gs protein to adenylyl cyclase
and cyclic AMP production.
Prostacyclin can also bind to and
activate other prostanoid
receptors, including EP3 and TP in
human pulmonary arteries, and
platelets and EP1 and TP in
pulmonary veins. These receptors
counteract IP receptor signalling
by elevating intracellular Ca2+
and/or lowering cyclic AMP
though Gq, Gi and an unknown G
protein pathway. AC, adenylyl
cyclase; cAMP, cyclic adenosine
monophosphate; DAG,
diacylglycerol; G, G protein; IP3,
inositol triphosphate; PGE2,
prostaglandin E2; PGI2,
prostacyclin; PKA, protein kinase
A; PLC, phospholipase C; PIP2,
phosphatidylinositol 4,5-
bisphosphate; TXA2,
thromboxane.
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both human pulmonary smooth muscle cells (PASMCs) and
mouse alveolar macrophages, suggesting signalling through
additional Gs protein-coupled receptors,34,35 largely
accounted for in macrophages by activation of EP2 but not
EP4 receptors. Thus prostacyclin agonists can act upon dif-
ferent cellular targets, meaning a similar spectrum of clini-
cal effects cannot be readily assumed with this class of agents.
IMPACT OF PAH ON PROSTACYCLIN SIGNALLING
Several studies point to defects in prostacyclin signalling in
PAH which may either contribute to disease pathology
and/or explain why prostacyclin therapy wanes as the dis-
ease progresses, necessitating doses to be increased.
Decreased urinary levels of 2,3-dinor-6-keto-PGF1α are
found in patients with IPAH36 or pulmonary hypertension
linked with congenital heart disease.37 In IPAH this is asso-
ciated with a progressive loss of PGI2 synthase expression
from large to small pulmonary arterial vessels, with virtu-
ally no expression in plexiform lesions.38 Conversely over-
expression of PGI2 synthase is protective in monocrotaline-
and hypoxic-induced models of PAH, reducing both medi-
al thickening and pulmonary pressure.39,40 A reduction in
IP receptor expression has recently been reported in IPAH
lungs or in rats following monocrotaline treatment.33 Such
a loss is, however, unlikely to cause PAH, as mice lacking
the IP receptor gene do not spontaneously develop pul-
monary hypertension, although they are more susceptible
to the hypertensive and remodelling effects of hypoxia.41
Thus, PGI2 synthase and the IP receptor both appear pro-
tective in the context of PAH. 
For a number of reasons, IP receptor desensitisation is
likely to be a problem with the long-term use of prostacy-
clin. Analogues are known to induce rapid time- and con-
centration-dependent phosphorylation and internalisation
of the IP receptor,42 with desensitisation lasting for several
hours after agonist removal.43 The mechanism of receptor
desensitisation is mutifactorial and involves both PKA and
protein kinase C (PKC). Cross-desensitisation can also
occur via EP130 or thromboxane A244 receptors being acti-
vated either by prostacyclin agonists themselves or by
increased production of their respective endogenous lig-
ands, PGE2 or thromboxane A2, both of which can increase
in lung disease.36,45
Heightened activity of PDE1 (PDE1A and PDE1C)14,46and
to a lesser extent PDE3 has been reported in IPAH,14 sug-
gesting this may lead to reduced effectiveness of prostacyclin
and its analogues. Indeed, blockade of PDE1 and PDE3
restored the ability of beraprost to increase cAMP levels in
pulmonary smooth muscle cells derived from IPAH
patients.14 In addition, only a combination of iloprost with a
PDE1 or PDE3 inhibitor could reverse pulmonary hyper-
tension and distal pulmonary artery muscularisation induced
by chronic hypoxia.13 Likewise, in a chronic monocrotaline
model, combined administration of iloprost and a mixed
PDE3/4 PDE inhibitor was required to fully normalise
haemodynamic and right heart changes when administered
after full establishment of pulmonary hypertension.5 Taken
together, this suggests that a PDE1 inhibitor and/or a PDE3
inhibitor might be useful in potentiating analogue effects in
the clinical setting. The role of PDE4 is less clear.
The extent to which IPAH impacts on PPAR isoform
expression is relatively unexplored. Ameshima and col-
leagues found reduced staining of PPARγ in IPAH lungs and
none in the proliferating cells of plexiform lesions.47
Similarly, PPARγ expression was also significantly reduced
in the vascular lesions in a rat model of severe PAH caused
by hypoxia in the presence of a vascular endothelial growth
factor (VEGF) blocker. Moreover, PPARγ knockdown in
endothelial cells leads to an abnormal, proliferating, apop-
tosis-resistant phenotype,47 while targeted deletion of
PPARγ in smooth muscle causes pulmonary hypertension
and muscularisation of distal pulmonary arteries.48 Thus loss
of PPARγ is likely to impact on disease severity. In contrast,
PPARγ ligands (e.g. rosiglitazone) can protect against the
pulmonary effects of monocrotaline and hypoxia (see Nisbet
et al.16). Therefore, depletion of two co-existing prostacyclin
targets (IP receptor and PPARγ) in proliferating intimal cells
may contribute both to uncontrolled vascular remodelling
and, in conjunction with receptor desensitisation, to lack of
responsiveness of prostacyclin agents in advanced disease.
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Table 1. Receptor binding affinities (Ki) of prostacyclin analogues to human and mouse prostanoid receptors
Ligands IP DP TP EP1 EP2 EP3 EP4
Carbacyclin
Human 282 132 23 942 14 352
Mouse 110 1600 31 2300
Cicaprost
Human 17 >1340 >1340 >1340 >1340 255 44
Mouse 10 1300 170
Iloprost
Human 11 1035 11 1870 56 284
Mouse 11 21 1600 27 2300
Beraprost
Human 39 680
Mouse 16 110
Treprostinil
Human 8** ND ND ND ND ND ND
Mouse YES ND ND ND YES ND NO
PGE2
Human YES 307 9.1 4.9 0.33 0.79
Mouse 20 12 0.85 1.9
Radioligand binding data (Ki in nM) has been taken from references.12,29,80 Blank means Ki value >3μM, ND means not done, YES indicates evidence for functional activity and NO means the
opposite. **Ki value taken from cAMP generation in cultured human pulmonary smooth muscle cells.31 
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cellular calcium levels would inhibit the phosphatase activity
of calcineurin, thereby maintaining NFAT in the phosphory-
lated state and preventing its translocation into the nucleus
(see Jabr et al.59). Such a mechanism may counteract the ele-
vated NFAT activity and expression reported in IPAH or in
remodelled pulmonary arteries.54 Furthermore, this tran-
scription factor appears largely responsible for the downreg-
ulation of voltage-gated (Kv) current and Kv1.5 expression
reported in human PASMCs from these patients,53 as well as
the expression of pro-inflammatory cytokines and growth-
promoting genes (including endothelin-1) in a number of dif-
ferent cell types.54,60 Prostacyclin analogues have been
reported to reduce ET-1 synthesis stimulated by mitogens in
PASMCs61,62 and to reduced elevated plasma levels in patients
with systemic sclerosis.63 Whether this relates to inhibition of
NFAT activity, which itself can be suppressed by a direct inter-
action of PPARγ,19 remains to be determined. 
Activation of PPARs is also likely to contribute to the
antiproliferative effects of PGI2 agents in a variety of cell types.
Recent studies have shown that PPARγ contributes to the IP
receptor-dependent antiproliferative effects of treprostinil in
HEK293 cells22 and to iloprost-induced inhibition of lung
tumourigenesis.23 In the latter study, pulmonary-specific
overexpression of either PGI2 synthase or PPARγ resulted in
suppression of tumour incidence and multiplicity in these
lung models,23 while gene deletion of the IP receptor had no
effect on tumour growth. Furthermore, non-small cell lung
cancer cells overexpressing PPARγ exhibit significantly less
invasiveness and metastases.23 Taken together, this suggests
a key role for both PGI2 and PPARγ in regulating cancer pro-
gression. A contribution from PPARβ was ruled out on the
basis that iloprost could not activate a PPARβ-specific
response element in lung epithelial cells.23 Furthermore,
PPARβactivation is consistently associated with human lung
carcinoma cell growth (e.g. Han et al.64). This contrasts with
other studies where PPARβ appears to mediate the antipro-
liferative effects of treprostinil in human lung fibroblasts65 or
beraprost in cultured rat aortic smooth muscle.21 However,
PPAR activation occurred in the micromolar range, suggest-
ing these effects may lie outside the therapeutic concentra-
tion range. That aside, the role of PPARβ in the cardiovascular
system is complex since overexpression of PPARβ actually
promotes vascular smooth muscle proliferation and
atherosclerosis, while PPARβ ligands appear to do the oppo-
site and also cause vasorelaxtion.17
VASCULAR WALL REMODELLING 
The aggressive pulmonary vascular obliterative disease char-
acteristic of IPAH involves all cell types within the vessel wall.
Smooth muscle cells are initially hyperplastic and hypertro-
phied, and then become atrophied as intimal proliferation
develops. Adventitial fibroblasts proliferate and migrate.
Endothelial damage is marked and plexiform lesions are
thought to consist of proliferating abnormal endothelial
cells, which may sometimes consist of monoclonal endothe-
lial cell expansion.54,66 Thus, it comes as no surprise that
patients with IPAH have elevated levels of several growth
factors, including PDGF, VEGF, epidermal growth factor
and angiopoietin.54,55,67 These agents induce proliferation
and migration of smooth muscle, endothelial cells and
fibroblasts, while VEGF and angiopoietin (1 and 2) are also
key markers of angiogenic remodelling. Metalloproteinases
(MMPs), which are also elevated in PAH67 and other inflam-
matory lung diseases,19 contribute to structural remodelling
PROSTACYCLIN AND VASCULAR TONE
A large body of evidence suggest that PGI2 analogues inhib-
it vascular tone almost exclusively through plasma mem-
brane potassium channels, activation of which will inhibit
calcium influx through voltage-dependent calcium chan-
nels.32,49,50 Potassium channels are able to influence vascu-
lar tone because of the very steep relationship between
membrane potential and calcium influx, with a small
change (<5 mV) capable of enhancing calcium entry two-
fold.50 Depending on the vascular bed studied, ATP-sensi-
tive (KATP), large conductance Ca2+-activated (BKCa) and
inward rectifier potassium channels have been implicated
in the relaxation induced by iloprost, beraprost and tre-
prostinil.31,32,49 This can occur through both cAMP-depen-
dent activation of PKA or by direct Gs protein coupling of
the IP receptor to the channel.49 In some blood vessels cAMP
does not appear to mediate relaxation at all, suggesting IP
receptors probably couple through other G protein sig-
nalling pathways, the nature of which remain unknown.32
In the lung, KATP and BKCa channels contribute to the
reversal by iloprost of hypoxic-induced increases in perfu-
sion pressure in the rat,51 while treprostinil activates a PKA-
sensitive background potassium (TASK-1) current which
is turned off by hypoxia and ET-1 in human PASMCs.52 In
addition, depressed activity and expression of voltage-gated
(Kv) potassium channels (in particular Kv1.5) is consis-
tently reported in response to hypoxia, serum, anorexic
agents, ET-1 and in IPAH.50,53,54 Moreover, serum and ET-
1 will also inhibit KATP channel function, though prolifer-
ating human PASMCs are still able to hyperpolarise to
pharmacological openers. The combined loss of potassium
function will lead to PASM depolarisation and a sustained
rise in intracellular calcium, triggering not only vasocon-
striction but cell proliferation and a reduction in apoptoic
signals (reviewed in Clapp and Tennant,50 Morrell et al.54
and Hassoun et al.55). Thus, potassium channel activation
is likely to underlie some of the beneficial effects of PGI2
therapy, possibly counteracting potassium channel dys-
function induced as a consequence of PAH.
IP RECEPTOR AND PPARS AS REGULATORS OF CELL
PROLIFERATION  
Previous studies in normal human PASMCs have shown that
prostacyclin analogues can inhibit the mitogenic responses
to PDGF and serum in a largely cAMP-dependent manner,
with adenylyl cyclase inhibitors blocking around 75% of the
analogue responses in these cells.34,56 The downstream
mechanisms are not well understood, but prostacyclin ana-
logues appear to inhibit smooth muscle cell proliferation by
blocking progression from G1 to S phase.57,58 This may occur
through phosphorylation of the cAMP response element-
binding protein (CREB) inhibiting cyclin A expression57 and
upregulating the inducible cAMP early repressor;58 the lat-
ter pathway is thought to promote apoptosis as well. 
There are other mechanisms by which cAMP cascades can
impede cell growth. Treprostinil inhibits serum-induced cell
growth in human PASMCs in part through cAMP-dependent
activation of ATP-sensitive potassium (K+) channels.50In aor-
tic smooth muscle cells, cAMP elevating agents inhibit
platelet-derived growth factor (PDGF) proliferation through
inhibition of the calcineurin and NFAT (nuclear factor of acti-
vated T-cells) pathway.59 The exact mechanism was not fully
explored, but PKA is known to promote the nuclear export
of the calcineurin/NFAT complex, while a lowering of intra-
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by growth factor activation, degradation of extracellular
matrix proteins (collagens, gelatins and proteoglycans) and
disruption of the internal elastic lamina. Furthermore, in
monocrotaline-treated animals, increases in MMP-9 and
MMP-2 proteins levels and activity were somewhat sup-
pressed by iloprost treatment, but co-treatment was required
with a PDE3/4 inhibitor to have significant effects and return
levels to those seen in control animals.5 Thus, the mecha-
nism of suppression is likely to involve cAMP, though
PPARαγand PPARγ ligands are also potent suppressors of
MMP-9 and MMP-2 activity.19
The effects of PGI2 on remodelling markers in patients is
largely unknown though clinical improvement with tre-
prostinil treatment for 12 weeks in a placebo-controlled trial
was correlated with a reduction in angiopoietin-2 and
MMP-9 plasma levels, with a trend towards lower PDGF
levels.67 In contrast, circulating VEGF levels were actually
found to be significantly enhanced by treatment and
patients were clinically worse (as assessed by the 6-minute
walk test) the higher the change from baseline.67 Indeed
many studies have shown increased VEGF production with
prostacyclin agents (e.g. Eddahibi et al.68 and Biscetti et
al.69). Moreover, iloprost can induce angiogenesis in vivo,
an effect ameliorated by sequestering VEGF with soluble
Flt-1 or by gene deletion of PPARα.69 Whether this high-
lights a potential unwanted side-effect of prostacyclin
agents is far from clear and warrants further investigation. 
On the one hand, it is becoming increasingly accepted that
the success of any therapy, at least for severe PAH, requires
endothelial cell growth to be controlled or perhaps
reversed.54,66 Thus therapies utilised in cancer are currently
being trialled in PAH.55,66 On the other hand, VEGF stimu-
lates nitric oxide and PGI2 production in endothelial cells and
is critical for maintaining endothelial integrity.54,66Indeed, this
latter concept is supported by studies showing that VEGF
receptor blockade causes mild pulmonary hypertension and
muscularisation of pulmonary arteries associated with
endothelial cell death and also exacerbates the effects of chron-
ic hypoxia, with animals presenting with severe PAH and
occlusive vascular lesions (see Stenmark et al.66). Thus it might
well be argued that aggressive prostacyclin treatment early on
in the disease, before the onset of extensive intimal prolifera-
tion and lesion formation, may offer the best chance of revers-
ing or slowing disease progression with this therapy. 
Perhaps another thing worth considering is that PGI2
analogues may only become angiogenic agents in cells
expressing low levels of IP receptor, PGI2 synthase and
PPARγ, as appears the case in cells contained within plexi-
form lesions (see comments above). Finally, one should
consider the possibility that there may be scenarios where
new blood vessel growth might be advantageous, perhaps
in critical limb ischaemia or in sclerodema patients with
Raynaud’s syndrome for whom ischaemic digital ulcers are
a major clinical problem. 
Interestingly, in an experimental model of flow-mediat-
ed pulmonary hypertension, improvement in right ven-
tricular function with iloprost was associated with a
restoration of capillary to myocyte ratio, with no detectible
change in vascular remodelling or pulmonary arterial pres-
sure, suggesting new capillary growth may improve a fail-
ing heart.70 It should be noted that this study failed to detect
any changes in message levels for VEGF or angiopoietin-2
after iloprost treatment for 28 days. Given that markers were
measured at the same time point as histological changes
were recorded, this may indicate that this was too late to
pick up changes associated with new vessel growth. 
ANTI-INFLAMMATORY ACTIONS OF PROSTACYCLIN
Endothelial dysfunction plays a key role in the development
of PAH and this in turn causes the expression of adhesion
molecules (e.g. P-selectin, ICAM-1) and the subsequent
adherence of platelets and leukocytes to the injured endothe-
lium.7,55,71 Extensive infiltration of T-lymphocytes,
macrophages and dendritic cells occurs in the distal arteries
and plexiform lesions of children and adults with IPAH,7,55,66
culminating in an environment where pro-inflammatory
cytokines, particularly interleukins 1 (IL-1) and 6 (IL-6) and
chemokines (e.g. CCL2, also known as monocyte chemotac-
tic protein, MCP-1) are upregulated.55 It is becoming increas-
ingly recognised that the anti-inflammatory actions of
prostacyclin may contribute to the beneficial effects of these
agents in PAH as well as in critical limb ischaemia or scle-
rodema. Prostacyclin and in particular iloprost are capable of
inhibiting the expression of selectins (P and E) and the adhe-
sion molecules ICAM and VCAM in endothelial or inflam-
matory cells of patients with PAH, systemic sclerosis and
peripheral vascular disease.63,72,73 Furthermore, analogues can
downregulate pro-inflammatory cytokine (TNF-α, IL-1 IL-
6 and interferon-γ) and chemokine production (MCP-1 and
granulocyte macrophage colony-stimulating factor) in
response to bacterial products in alveolar macrophages,74den-
dritic cells75 and T-lymphocytes.76 NF-κB plays a critical role
in the expression of proinflammatory cytokines and
chemokines in these inflammatory cell types, and analogues
suppress NF-κB activity74–76 in a largely, though not exclu-
sively, IP receptor-driven manner, in part involving PKA.75,76
Studies in patients are limited, though iloprost-inhibited plas-
ma TNF-α levels in critical limb ischaemia.77 In IPAH,
epoprostenol treatment reduced elevated circulating levels of
MCP-1,78 and in combination with bostantan, significantly
reduced human leukocyte antigen–DR expression, a marker
of endothelial cell activation.7 Whether PPARs are involved
in analogue suppression of inflammatory mediators remains
to be determined, though in the lung, PPARα and to a lesser
extent PPARγ are regulators of adhesion molecule expression,
Figure 3. Schematic
representation of the cellular
pathways by which prostacyclin
inhibits vascular tone, cell
proliferation, platelet activation and
inflammation. AC, adenylyl cyclase;
CREB, cAMP response element
binding protein; cAMP, cyclic
adenosine monophosphate; COX-
2, cyclooxygenase-2; ECM,
extracellular matrix; ET, endothelin,
ETR, endothelin receptor; ICAM,
intercellular adhesion molecule;
IFγ, interferon-γ; IL-1, interleukin-
1; IL-6, interleukin-6; IP,
prostacyclin receptor; NFAT,
nuclear factor of activating T-cells;
NF-κB, nuclear factor kappa B;
MMP, metalloproteinase; MCP,
monocyte chemoattractant protein;
PGI2, prostacyclin; PGH2,
prostaglandin H2; PKA, protein
kinase A; PPARs, peroxisome
proliferator-activated receptors;
SMC, smooth muscle cell; TNF-α,
tumour necrosis factor α; VCAM,
vascular cell adhesion molecule-1.
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while both PPARα and PPARγ are major inhibitors of pro-
inflammatory cytokine production via transrepression of NF-
κB.17,20 By comparison, little is known about the role of
PPARβ, but it has been implicated in the antithrombotic
effects of treprostinil in human platelets.79
CONCLUDING REMARKS
Prostacyclin can no longer be considered a hormone that
just produces its biological effects through activation of the
IP receptor. The family of transcription factors knows as
PPARs must now be considered a target through which
prostacyclin or its stable analogues can modulate cell growth,
endothelial cell activation, inflammation and apoptosis and
produce beneficial effects in PAH (Figure 3). While PPARs
can be activated independently of the IP receptor, few stud-
ies have considered the role membrane receptors (or for that
matter cAMP) either in inducing activation or modulating
ligand binding. The future challenge will be in identifying
the role of specific PPAR isoforms not only the aetiology of
PAH, but also in response to analogue activation. 
The role of VEGF in PAH (vascular protective vs. angio-
genic) is clearly an area that needs further investigation, in
particular whether upregulation of this growth factor by
prostacyclin analogues is detrimental in PAH patients or
contributes to lack of efficacy in end-stage disease. Given
that the aim of any treatment is to reverse the remodelling
process, then the possibility of earlier and aggressive inter-
vention with prostacyclin agonists should be considered. 
Finally, prostacyclin agonists differ in their pharmaco-
logical profile, meaning that the clinician should not read-
ily assume they are dealing with a homogenous class of
agents when it comes to clinical treatment or side-effect pro-
file. It may be that such differences can be exploited in future
therapies or be utilised to tease out the role of different
prostanoid receptor subtypes.
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